22174 The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting
The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments.
This activity can be accessed using the following URL: www.peerview.com/BJB
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other healthcare professionals involved in the care of patients with MF.
Upon completion of this activity, participants should be better able to:
- Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF)
- Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF
- Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF
- Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Jeanne M. Palmer, MD
Associate Professor, Division of Hematology and Oncology
Vice Chair and Section Lead, Division of Hematology
Program Director, Blood and Marrow Transplant Program
Jeanne M. Palmer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for CTI BioPharma Corp. and Sierra Oncology, Inc.
Grant/Research Support from PharmaEssentia Corporation.
Srdan Verstovsek, MD, PhD
Professor of Medicine
Director, Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Srdan Verstovsek, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.